ICB combined with targeted therapy
ICBs
CERVICAL CANCER
Targeted therapies have countered lots of difficulties in the treatment of advanced cervical cancer, making it necessary and urgent to develop other novel therapies. And in this situation, immunotherapy has been regarded as a new hope, especially when it is combined with other therapies. Currently, the combined regimen that use both ICBs and targeted therapies such as small-molecule inhibitors is widely being studied in clinical trials, some of which has represented promising results.Sintilimab plus Anlotinib. Anlotinib is a multi-targeting tyrosine kinase inhibitor (TKI) with targets on VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), and c-kit (Nivolumab plus Lucitanib. Lucitanib is an antiangiogenic TKI that selectively inhibits VEGFR 1−3, FGFR 1−3, and PDGFRα/β (Currently, there are 25 ongoing phase II (phase I/II) clinical trials using this treatment pattern in patients with advanced cervical cancer in our study. And in these trials, targeted inhibitions especially multi-targeting tyrosine kinase inhibitors such as Anlotinib, Famitinib, Lenvatinib, and Cabozantinib are widely applied.